The Week

Upstream Bio (UPB) fell 41.28% on the week to close at $2.76, while the S&P 500 gave back 1.95%—underperforming by about 39.33 percentage points. The stock slid in a mostly one-way move: Monday (12 Oct) opened at $4.68 and hit a session high of $4.72, then drifted lower each day. By Friday (16 Oct), the stock traded as low as $2.74, just above the close. That low sits near the bottom of its 60-day range. Volume picked up on the way down, with daily turnover running well above the week’s median. There was no major company catalyst this week; the move tracked broader biotech sentiment and a heavy selling bias.

Analyst Ratings

Seven brokers cover UPB: four rate it buy, one overweight, and two hold. The consensus rating is buy, with a consensus target of $31.14286—about 1,028.36% above the latest price of $2.76. Targets range from $9.000 to $75.000, a wide spread of more than eight times between the low and high end, reflecting very different assumptions across the Street. Within the biotechnology industry, UPB ranks 227th out of 509 names, in the lower-middle part of the peer group.

The Week Ahead

On the macro calendar, US housing data dominates early next week: the NAHB Housing Market Index arrives Monday (19 Oct), with both prior and forecast at 32. Tuesday (20 Oct) brings housing starts annualised—prior 1.275, forecast 1.305—and building permits annualised, prior 1.403, forecast 1.395. Wednesday (21 Oct) adds the EIA weekly crude oil and Cushing inventories. For UPB itself, no earnings or company events are on the schedule next week. The main watch item is whether the biotech sector stabilises after this week’s pullback and whether buyers step back in.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.